{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:58:43Z","timestamp":1789153123839,"version":"build-2803163510"},"reference-count":54,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophilia stands out among rare genetic diseases for its significant therapeutic advancements, closely tied to substantial financial investments. Key factors driving this progress include severe hemorrhagic consequences from an early age, its impact on royal families, the HIV and hepatitis C contamination tragedies, the identification of factor VIII (FVIII) and FIX genes, and advancements in biotechnology. Maintaining low, measurable concentrations of FVIII or FIX in the blood has proven pivotal in improving patient outcomes. The mobilization of the global hemophilia community, led by the World Federation of Hemophilia, the European Association for Haemophilia and Allied Disorders, and the National Bleeding Disorder Foundation, has continuously advocated for access to safe, effective treatments. With reinvestments from biopharmaceutical partners, revolutionary options, including gene therapy, have emerged. However, this cycle of innovation and investment, essential for curing all patients worldwide, faces potential threats. This article aims to highlight the critical importance of investing in hemophilia treatment and research, a topic of concern for all stakeholders within the hemophilia community.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016497","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:02:02Z","timestamp":1751367722000},"page":"4631-4639","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic innovations in hemophilia: the essential role of a positive reinvestment cycle"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-8437","authenticated-orcid":false,"given":"Cedric","family":"Hermans","sequence":"first","affiliation":[{"name":"1Hemostasis and Thrombosis Unit, Division of Hematology, Saint-Luc University Hospital, Universit\u00e9 catholique de Louvain, Brussels, Belgium"},{"name":"2World Federation of Hemophilia, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3310-328X","authenticated-orcid":false,"given":"Glenn F.","family":"Pierce","sequence":"additional","affiliation":[{"name":"2World Federation of Hemophilia, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"1","key":"2025092310370832800_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primer"},{"issue":"10480","key":"2025092310370832800_bib2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","article-title":"Haemophilia","volume":"405","author":"Chowdary","year":"2025","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"2025092310370832800_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2025092310370832800_bib4","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1111\/j.1538-7836.2006.02213.x","article-title":"The tragic history of AIDS in the hemophilia population, 1982-1984","volume":"4","author":"Evatt","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2025092310370832800_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"2025092310370832800_bib6","doi-asserted-by":"crossref","first-page":"e224631","DOI":"10.1001\/jamahealthforum.2022.4631","article-title":"Value-based pricing of US prescription drugs: estimated savings using reports from the Institute for Clinical and Economic Review","volume":"3","author":"Yeung","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"4","key":"2025092310370832800_bib7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol Ther"},{"issue":"4","key":"2025092310370832800_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"2025092310370832800_bib9","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jtha.2024.04.010","article-title":"Ultra-long factor VIII: a major step forward toward a hemophilia-free mind","volume":"22","author":"Hermans","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025092310370832800_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa2312611","article-title":"Efanesoctocog alfa prophylaxis for children with severe hemophilia A","volume":"391","author":"Malec","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"2025092310370832800_bib11","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2025092310370832800_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2025092310370832800_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"2025092310370832800_bib14","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","article-title":"Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies","volume":"6","author":"Kruse-Jarres","year":"2022","journal-title":"Blood Adv"},{"key":"2025092310370832800_bib15","unstructured":"World Bank Group\n          . World development indicators. Accessed 4 May 2025. https:\/\/databank.worldbank.org\/indicator\/NY.GNP.PCAP.CD\/1ff4a498\/Popular-Indicators."},{"issue":"1","key":"2025092310370832800_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-0044-1796651","article-title":"Non-factor therapies for hemophilia: achievements and perspectives","volume":"51","author":"Jim\u00e9nez-Yuste","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2025092310370832800_bib17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"23","key":"2025092310370832800_bib18","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1182\/bloodadvances.2024014111","article-title":"Adeno-associated virus-based gene therapy for hemophilia A and B: a systematic review and meta-analysis","volume":"8","author":"Deshpande","year":"2024","journal-title":"Blood Adv"},{"key":"2025092310370832800_bib19","unstructured":"World Health Organization\n          . Proposal for the inclusion of recombinant coagulation factor VIII and IX therapeutics for hemophilia on the core list of WHO model list of essential medicines (EML) and the list of essential medicines for children (EMLc). Accessed 4 May 2025. https:\/\/cdn.who.int\/media\/docs\/default-source\/2025-eml-expert-committee\/addition-of-new-medicines\/a.23_recombinant-cfcs.pdf?sfvrsn=9dba590d_9."},{"key":"2025092310370832800_bib20","unstructured":"Grand View Research\n          . Hemophilia market size, share & trends analysis report by type (hemophilia A, hemophilia B), by treatment type (on-demand, cure), by therapy, by distribution channel, by region, and segment forecasts, 2025 \u2013 2030. Accessed 4 May 2025. https:\/\/www.grandviewresearch.com\/industry-analysis\/hemophilia-treatment-industry\/request\/rs1."},{"issue":"6","key":"2025092310370832800_bib21","doi-asserted-by":"crossref","first-page":"e2415445","DOI":"10.1001\/jamanetworkopen.2024.15445","article-title":"Costs of drug development and research and development intensity in the US, 2000-2018","volume":"7","author":"Sertkaya","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2025092310370832800_bib22","doi-asserted-by":"crossref","first-page":"e2453275","DOI":"10.1001\/jamanetworkopen.2024.53275","article-title":"Use of clinical trial characteristics to estimate costs of new drug development","volume":"8","author":"Mulcahy","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"9","key":"2025092310370832800_bib23","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2352-3026(22)00209-5","article-title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded humanitarian aid program of the World Federation of Hemophilia after 5 years","volume":"9","author":"Pierce","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025092310370832800_bib24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jtha.2023.12.027","article-title":"The underevaluated impacts of the therapeutic revolution of hemophilia on women and girls","volume":"22","author":"Hermans","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2025092310370832800_bib25","article-title":"Hemophilia market size to hit USD 24.2 billion by 2032, driven by advancements in gene therapy and innovative treatment solutions \u2013 SNS Insider","year":"12  2025","journal-title":"GlobeNewswire"},{"issue":"5","key":"2025092310370832800_bib26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/hae.14595","article-title":"Befovacimab, an anti-tissue factor pathway inhibitor antibody: early termination of the multiple-dose, dose-escalating phase 2 study due to thrombosis","volume":"28","author":"Mancuso","year":"2022","journal-title":"Haemoph"},{"key":"2025092310370832800_bib27","article-title":"Centessa drops phase 2 hemophilia B drug in wake of Pfizer\u2019s Hympavzi approval","author":"Waaldron","year":"2024","journal-title":"Fierce Biotech"},{"issue":"4","key":"2025092310370832800_bib28","doi-asserted-by":"crossref","first-page":"e12508","DOI":"10.1002\/rth2.12508","article-title":"Disruptive technology and hemophilia care: the multiple impacts of emicizumab","volume":"5","author":"Hermans","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2025092310370832800_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/hae.14470","article-title":"Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?","volume":"28","author":"Holstein","year":"2022","journal-title":"Haemophilia"},{"issue":"2","key":"2025092310370832800_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/hae.15112","article-title":"The impact of emicizumab on the clinical validation of new therapies for haemophilia A","volume":"31","author":"Hermans","year":"2024","journal-title":"Haemophilia"},{"issue":"19","key":"2025092310370832800_bib31","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2025092310370832800_bib32","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2025092310370832800_bib33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa2410597","article-title":"Lentiviral gene therapy with CD34+ hematopoietic cells for hemophilia A","volume":"392","author":"Srivastava","year":"2025","journal-title":"N Engl J Med"},{"key":"2025092310370832800_bib34","unstructured":"U.S. Food and Drug Administration\n          . FDA approves novel treatment for hemophilia A or B, with or without factor inhibitors. 2025. Accessed 4 May 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors."},{"key":"2025092310370832800_bib35","unstructured":"U.S. Food and Drug Administration\n          . FDA approves drug to prevent or reduce the frequency of bleeding episodes for patients with hemophilia A with inhibitors or hemophilia B with inhibitors. 2024. Accessed 4 May 2025. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-prevent-or-reduce-frequency-bleeding-episodes-patients-hemophilia-inhibitors-or."},{"key":"2025092310370832800_bib36","unstructured":"U.S. Food and Drug Administration\n          . FDA approves new treatment for hemophilia A or B. 2024. Accessed 4 May 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-hemophilia-or-b."},{"issue":"10","key":"2025092310370832800_bib37","first-page":"1183","article-title":"Updates on novel non-replacement drugs for hemophilia","volume":"15","author":"Gualtierotti","year":"2022","journal-title":"Pharm Basel Switz"},{"issue":"1","key":"2025092310370832800_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/hae.15125","article-title":"UKHCDO gene therapy taskforce: guidance for implementation of haemophilia gene therapy into routine clinical practice for adults","volume":"31","author":"Chowdary","year":"2024","journal-title":"Haemophilia"},{"issue":"9","key":"2025092310370832800_bib39","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the grading of recommendations assessment, development, and evaluation methodology","volume":"22","author":"Rezende","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2025092310370832800_bib40","doi-asserted-by":"publisher","DOI":"10.1111\/hae.15135","article-title":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital haemophilia-A critical appraisal","author":"Albisetti","year":"6  2024","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"suppl 6","key":"2025092310370832800_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"4","key":"2025092310370832800_bib42","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/hae.14807","article-title":"Towards achieving a haemophilia-free mind","volume":"29","author":"Hermans","year":"2023","journal-title":"Haemophilia"},{"issue":"1","key":"2025092310370832800_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.13862","article-title":"Achieving the unimaginable: health equity in haemophilia","volume":"26","author":"Skinner","year":"2020","journal-title":"Haemophilia"},{"issue":"9","key":"2025092310370832800_bib44","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1016\/S2352-3026(21)00132-0","article-title":"The case for equitable haemophilia care","volume":"8","author":"Srivastava","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025092310370832800_bib45","doi-asserted-by":"crossref","first-page":"101029","DOI":"10.1016\/j.blre.2022.101029","article-title":"Molecular basis of rare congenital bleeding disorders","volume":"59","author":"Dorgalaleh","year":"2023","journal-title":"Blood Rev"},{"key":"2025092310370832800_bib46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcmd.2017.02.003","article-title":"Rare bleeding disorders-old diseases in the era of novel options for therapy","volume":"67","author":"Livnat","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"18","key":"2025092310370832800_bib47","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"Weyand","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2025092310370832800_bib48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s44161-023-00418-4","article-title":"A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders","volume":"3","author":"Gandhi","year":"2024","journal-title":"Nat Cardiovasc Res"},{"issue":"2","key":"2025092310370832800_bib49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.2023023404","article-title":"Fitusiran reduces bleeding in factor X-deficient mice","volume":"144","author":"Verhenne","year":"2024","journal-title":"Blood"},{"issue":"suppl 3","key":"2025092310370832800_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14970","article-title":"Diagnosis and treatment of von Willebrand disease in 2024 and beyond","volume":"30","author":"James","year":"2024","journal-title":"Haemophilia"},{"issue":"3-4","key":"2025092310370832800_bib51","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41434-020-00218-6","article-title":"Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor","volume":"30","author":"Barbon","year":"2023","journal-title":"Gene Ther"},{"issue":"4","key":"2025092310370832800_bib52","doi-asserted-by":"crossref","first-page":"e230511","DOI":"10.1001\/jamahealthforum.2023.0511","article-title":"Comparison of research spending on new drug approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019","volume":"4","author":"Galkina Cleary","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"4","key":"2025092310370832800_bib53","doi-asserted-by":"crossref","first-page":"e0227593","DOI":"10.1371\/journal.pone.0227593","article-title":"Mapping the coevolution, leadership and financing of research on viral vectors, RNAi, CRISPR\/Cas9 and other genomic editing technologies","volume":"15","author":"Fajardo-Ortiz","year":"2020","journal-title":"PLoS One"},{"key":"2025092310370832800_bib54","article-title":"NIH funding cuts put innovation, health equity, and lives at risk","author":"Alvaro","year":"10  2025","journal-title":"Pharma\u2019s almanac"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4631\/2412076\/blooda_adv-2025-016497-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4631\/2412076\/blooda_adv-2025-016497-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:37:19Z","timestamp":1758638239000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/18\/4631\/538043\/Therapeutic-innovations-in-hemophilia-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":54,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016497","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,23]]},"published":{"date-parts":[[2025,9,12]]}}}